LGND Q3 2025 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$115M+122.8% YoY

Gross Profit

$91M78.5% margin

Operating Income

$55M47.6% margin

Net Income

$117M101.6% margin

EPS (Diluted)

$5.68

QoQ Revenue Growth

+142.4%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$13M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$527M

Stockholders' Equity

$950M

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$115M	$52M	+122.8%
Gross Profit	$91M	$39M	+130.5%
Operating Income	$55M	$3M	+1647.7%
Net Income	$117M	-$7M	+1735.2%

Revenue Segments

Royalty

$47M38%

Intangible Royalty Assets

$40M32%

Kyprolis

$12M9%

Material Sales, Captisol

$11M9%

Financial Royalty Assets

$6M5%

Rylaze

$4M3%

Teriparatide Injection

$3M2%

Evomela

$2M2%

Contract Revenue

$131,0000%